THX-B
Modify Date: 2025-08-25 20:57:00
THX-B structure
|
Common Name | THX-B | ||
|---|---|---|---|---|
| CAS Number | 1372206-64-8 | Molecular Weight | 364.40 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H24N6O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of THX-BTHX-B is a potent and non-peptidic p75NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders[1][2][3]. |
| Name | THX-B |
|---|
| Description | THX-B is a potent and non-peptidic p75NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | THX-B (10 μM, 4 days) decreases proliferation of myoblasts[1]. THX-B (10 μM, 1 h) inhibits NGF-induced phosphorylation of ERK1/2 in C2C12 myoblasts[1]. THX-B (20 μM, 24 h) decreases photoreceptor cell death and reactive gliosis in cultured rd10 retinas[2]. Western Blot Analysis[1] Cell Line: C2C12 myoblasts Concentration: 10 μM Incubation Time: Pre-treated for 1 hour Result: Inhibited βNGF-induced ERK2 phosphorylation by 67%. Inhibited proNGF-induced ERK2 phosphorylation by 90%. Immunofluorescence[1] Cell Line: Cultured P22 rd10 retinas. Concentration: 20 μM Incubation Time: 24 h Result: Attenuated the thickening and enlargement of processes of astrocytes and Müller glia cells. |
| In Vivo | THX-B (50 μg in 125 μL PBS, i.p. weekly for 4 weeks) improves bladder function in a mouse model of diabetic voiding dysfunction[3]. THX-B (2 μL of 2 μg/μL, IVT injection, a single dose) elicits a neuroprotective effect on photoreceptor cells in P17 rd10 mice[2]. THX-B (40 μg in 20 μL, IVT injection) resolves the inflammatory, vascular, and neurodegenerative phases of the retinal pathology[4]. Animal Model: Mouse model of diabetic voiding dysfunction Dosage: 50 μg in 125 μL PBS Administration: Intraperitoneal injection (i.p.) Result: Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment. Animal Model: P17 rd10 mice[1] Dosage: 2 μL of 2 μg/μL, single dose Administration: Intravitreal (IVT) injected in one eye Result: Increased the number of photoreceptor rows as well as the ONL/INL ratio. Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα. |
| References |
| Molecular Formula | C16H24N6O4 |
|---|---|
| Molecular Weight | 364.40 |